Anixa Biosciences Reports Encouraging Ovarian Cancer CAR-T Trial Survival Data, Gains Dose Escalation Approval
ANIX sits 31% above its 52-week low of $2.331.
Summary
Anixa Biosciences announced encouraging patient survival data from its Phase 1 ovarian cancer CAR-T trial and received regulatory approval to significantly escalate dosing, indicating positive progress for the therapy.
Key Events · Product Development and Regulatory · ANIX
-
Encouraging Patient Survival Data
Seven out of twelve patients in the Phase 1 ovarian cancer CAR-T trial have lived beyond their expected median survival of 3-4 months. Notably, one patient survived 28 months, three over one year (17, 15, 14 months), and three others 11, 8, and 8 months, with four patients currently alive.
-
Regulatory Approval for Significant Dose Escalation
The company received regulatory approval to amend the trial protocol, enabling dose escalation from the original range of 1x10^5 to 1x10^7 CAR-positive cells/kg to potentially as high as 1x10^9 cells/kg, representing a two-order-of-magnitude increase.
-
Clean Safety Profile
No dose-limiting toxicities (DLTs) have been observed to date across all treated patients, supporting the decision for substantial dose escalation.
-
Introduction of Lymphodepletion
The next patient cohort will receive lymphodepletion (cyclophosphamide and fludarabine) prior to CAR-T treatment, a strategy aimed at enhancing CAR-T expansion, persistence, and activity.
Analysis · ANIX · Life Sciences
Anixa Biosciences announced significant positive developments for its ovarian cancer CAR-T therapy, lira-cel, in a Phase 1 clinical trial. The observation of multiple patients substantially exceeding expected survival at low dose levels, coupled with a clean safety profile (no dose-limiting toxicities), is a strong indicator of potential clinical activity. The regulatory approval to escalate doses by up to two orders of magnitude is critical, as it allows researchers to explore the optimal therapeutic range, potentially leading to enhanced efficacy. The introduction of lymphodepletion in the next cohort further demonstrates a strategic approach to maximizing CAR-T cell expansion and activity. This news provides encouraging validation for Anixa's novel CAR-T technology and could significantly de-risk future development stages, positively impacting investor sentiment.
At the time of this filing, ANIX was trading at $3.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $98.8M. The 52-week trading range was $2.33 to $5.46. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.